Hauschild A, Kroeger H, Mitchison N A, Ugrinovic S, Zwingenberger K
Deutsches Rheuma-Forschungszentrum, Berlin, Germany.
Clin Exp Immunol. 1997 Jun;108(3):428-31. doi: 10.1046/j.1365-2249.1997.3781274.x.
Thalidomide, a drug likely to affect the cytokine pattern, was administered orally to mice at various stages of CIA. Treatment (150 mg/kg per day by gavage, 5 days/week), started 6 weeks post-immunization, i.e. at the height of the disease, significantly reduced arthritis, and appeared also to reduce the level of inflammation as judged by neutrophil chemiluminescence. With treatment started 9 weeks post-immunization the effect on arthritis was no longer statistically significant, and when started at 14 weeks was lost. Over a dose range of up to 150 mg/kg per day the treatment had no effect on either interferon-gamma (IFN-gamma) or IL-4 mRNA levels. The treatment is therefore not likely to have operated via a shift in the Th1/Th2 balance.
沙利度胺是一种可能影响细胞因子模式的药物，在胶原诱导性关节炎（CIA）的不同阶段口服给予小鼠。治疗（通过灌胃每天150毫克/千克，每周5天）在免疫后6周开始，即在疾病高峰期开始，显著减轻了关节炎，并且从中性粒细胞化学发光判断，似乎也降低了炎症水平。在免疫后9周开始治疗，对关节炎的影响不再具有统计学意义，而在14周开始治疗时则失去了效果。在每天高达150毫克/千克的剂量范围内，该治疗对干扰素-γ（IFN-γ）或白细胞介素-4（IL-4）mRNA水平均无影响。因此，该治疗不太可能通过Th1/Th2平衡的转变起作用。
